Exercise aggravates cardiovascular risks and mortality in rats with disrupted nitric oxide pathway and treated with recombinant human erythropoietin.
Chronic administration of recombinant human erythropoietin (rHuEPO) can generate serious cardiovascular side effects such as arterial hypertension (HTA) in clinical and sport fields. It is hypothesized that nitric oxide (NO) can protect from noxious cardiovascular effects induced by chronic administration of rHuEPO. On this base, we studied the cardiovascular effects of chronic administration of rHuEPO in exercise-trained rats treated with an inhibitor of NO synthesis (L-NAME). Rats were treated or not with rHuEPO and/or L-NAME during 6 weeks. During the same period, rats were subjected to treadmill exercise. The blood pressure was measured weekly. Endothelial function of isolated aorta and small mesenteric arteries were studied and the morphology of the latter was investigated. L-NAME induced hypertension (197 ± 6 mmHg, at the end of the protocol). Exercise prevented the rise in blood pressure induced by L-NAME (170 ± 5 mmHg). However, exercise-trained rats treated with both rHuEPO and L-NAME developed severe hypertension (228 ± 9 mmHg). Furthermore, in these exercise-trained rats treated with rHuEPO/L-NAME, the acetylcholine-induced relaxation was markedly impaired in isolated aorta (60% of maximal relaxation) and small mesenteric arteries (53%). L-NAME hypertension induced an internal remodeling of small mesenteric arteries that was not modified by exercise, rHuEPO or both. Vascular ET-1 production was not increased in rHuEPO/L-NAME/training hypertensive rats. Furthermore, we observed that rHuEPO/L-NAME/training hypertensive rats died during the exercise or the recovery period (mortality 51%). Our findings suggest that the use of rHuEPO in sport, in order to improve physical performance, represents a high and fatal risk factor, especially with pre-existing cardiovascular risk.
EA4278 Physiology and Physiopathology of Cardiovascular Adaptations to Exercise, Faculty of Sciences, University of Avignon, Avignon, France. meziri_faycal@yahoo.fr
Fayçal
F
Meziri
Delphine
D
Binda
Sabeur
S
Touati
Maxime
M
Pellegrin
Alain
A
Berthelot
Rhian M
RM
Touyz
Pascal
P
Laurant
D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000401:mortality*; D015536:Down-Regulation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004921:Erythropoietin / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009026:Mortality; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000037:antagonists & inhibitors* / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D010805:Physical Conditioning, Animal / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000494:pharmacology; D012307:Risk Factors; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
C554270:EPO protein, human; D004791:Enzyme Inhibitors; D011994:Recombinant Proteins; D004921:Erythropoietin; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester
FASEB J. 2003 Feb;17(2):259-61
12490547
Contrib Nephrol. 1989;76:160-5; discussion 212-8
2684518
Blood. 1997 Jul 1;90(1):473-4
9207488
J Am Soc Nephrol. 2000 Feb;11(2):335-342
10665941
Circulation. 2000 Apr 25;101(16):1899-906
10779454
Pflugers Arch. 2000 Feb;439(4):445-8
10678740
Clin Physiol. 1998 Nov;18(6):521-8
9818157
J Vasc Res. 1997 Mar-Apr;34(2):117-25
9167644
BMC Physiol. 2008 May 29;8:12
18510739
J Appl Physiol (1985). 2003 Jul;95(1):20-5
12794092
Nephrol Dial Transplant. 1995;10 Suppl 2:74-9
7644110
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3974-8
8171022
Circulation. 1998 Dec 15;98(24):2709-15
9851957
J Cardiopulm Rehabil Prev. 2010 Jan-Feb;30(1):2-11
20040880
Clin Exp Hypertens. 1997 May;19(4):389-401
9140703
Sports Med. 2005;35(8):649-70
16076228
J Intern Med. 1991 Feb;229(2):125-30
1997637
Nephrol Dial Transplant. 1995 Oct;10(10):1814-9
8592587
Cardiovasc Res. 1999 Jan;41(1):9-13
10325946
Am J Physiol Heart Circ Physiol. 2002 Jan;282(1):H301-10
11748075
Hypertension. 1999 Mar;33(3):894-9
10082505
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11609-13
11027359
Sports Med. 2003;33(14):1013-35
14599231
Life Sci. 1994;54(16):PL253-9
8152333
Eur J Med Res. 1997 Mar 24;2(3):97-100
9113497
Cardiovasc Res. 2003 Sep 1;59(3):538-48
14499855
J Thorac Cardiovasc Surg. 2005 Sep;130(3):877-8
16153943
Med Sci Sports Exerc. 2006 Mar;38(3):445-54
16540831
Kidney Int. 1993 May;43(5):1010-4
8510379
Physiol Rev. 2008 Jul;88(3):1009-86
18626066
Sports Med. 2008;38(12):1009-24
19026018
J Appl Physiol (1985). 2009 Sep;107(3):896-902
19498093
Eur J Cardiovasc Prev Rehabil. 2008 Feb;15(1):52-8
18277186
Am J Physiol. 1993 Jan;264(1 Pt 2):H150-6
8381608